Colorectal Cancer
FOLFOX improved convenience in untreated metastatic colorectal cancer patients
Published in Clinical Oncology Week, May 16th, 2005
"This study determined the efficacy and safety of a modified FOLFOX regimen that improved patient convenience without compromising oxaliplatin dose intensity. A total of 62 patients with previously untreated metastatic colorectal cancer were enrolled to receive, entirely as outpatients, 2-weekly cycles of oxaliplatin 100 mg/m2 i.v. over 2 h, together with leucovorin 400 mg/m2 over 2 h, 5-fluorouracil (5-FU) 400 mg/m2, bolus, followed by a 46-h infusion of 5-FU at 2.4 g/m2," scientists reported in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- Chemotherapy
Surgery and chemotherapy for peritoneal colorectal carcinomatosis assessed - Complementary & Alternative Medicine
Herbal medicine may alter cell response to breast cancer drugs - Head & Neck Cancers
Patient and tumor factors associated with advanced carcinomas of head and neck - Human Papillomavirus
High-throughput, rapid, single-tube, HPV genotyping assay developed - Acute Cardiac Ischemia
Pharma company advances compound for diagnosis of acute cardiac ischemia - Acute Lymphoblastic Leukemia
RAS mutation associated with hyperdiploidy/parental characteristics in ALL - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
